Evidence map›Paper›PMID 36772971›Full record

ArticleAnnals of clinical and translational neurology2023

Ser77Tyr transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features.

Amir Dori, Michael Arad, Yishay Wasserstrum, Arthur Pollak, Vera Nikitin, Merav Ben-David, Jana Shamash, Ayelet Hashachar Nahum, Efrat Shavit-Stein, Liran Domachevsky and 6 more

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Amir DoriDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0003-4633-1481
Michael AradSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yishay WasserstrumSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Arthur PollakDepartment of Cardiology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Vera NikitinDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Israel.
Merav Ben-DavidDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Israel.
Jana ShamashThe Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
Ayelet Hashachar NahumThe Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
Efrat Shavit-SteinDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Israel.
Liran DomachevskySackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rafael KupersteinSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dan DominissiniSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Natalia ShelestovichSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Menachem SadehSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Elon PrasSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Lior GreenbaumSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-6176-0941
Tel Aviv University · ILSheba Medical Center · ILHebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAmyloidosis due to the transthyretin Ser77Tyr mutation (ATTRS77Y) is a rare autosomal-dominant disorder, characterized by carpal-tunnel syndrome, poly- and autonomic-neuropathy, and cardiomyopathy. However, related symptoms and signs are often nonspecific and confirmatory tests are required. We describe the age and frequency of early symptoms and diagnostic features among individuals of Jewish Yemenite descent in Israel.

methodsRecords of mutation carriers were retrospectively reviewed. ATTRS77Y diagnosis was defined by the presence of amyloid in tissue and/or amyloid-related cardiomyopathy.

resultsWe identified the Ser77Tyr mutation at the heterozygous state in 19 amyloidosis patients (mean age at diagnosis: 62 ± 5.7 years, range 49-70) and 30 amyloid-negative carriers. The probability for disease diagnosis increased from 4.4% at age 49 to 100% at 70 and occurred earlier in males. Initial symptoms preceded diagnosis by 5 ± 3.8 years (range 0-12) and were commonly sensory changes in the extremities. Erectile dysfunction predated these in 8/13 (62%) males. In two patients cardiac preceded neurological symptoms. Two patients declined symptoms. Electrophysiological studies near the time of diagnosis indicated a median neuropathy at the wrist in 18/19 (95%) and polyneuropathy in 13/19 (68%). Skin biopsy revealed epidermal denervation in 15/16 (94%) patients. Cardiomyopathy was identified in 16/19 (84%). Sensory complaints or epidermal denervations were present in 17/30 (57%) of amyloid-negative carriers and co-occurred in 10/30 (33%).

interpretationATTRS77Y symptoms commonly occur after age 50, but may begin earlier. Median neuropathy, skin denervation and cardiomyopathy are frequently identified. Symptoms may be absent in patients and common in amyloid-negative carriers.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesCarpal Tunnel SyndromeAgedAmyloidFemaleHumansIsraelMaleMiddle AgedPrealbuminRetrospective StudiesAmyloidPrealbumin

Identifiers

PMID36772971
PMCPMC10109316
OpenAlexW4320032949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.